Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ABBOTT's NEW NATIONAL HEALTH CARE ACCOUNTS UNIT

Executive Summary

ABBOTT's NEW NATIONAL HEALTH CARE ACCOUNTS UNIT will develop pharmaceutical marketing and customer service programs for HMOs, nursing homes, drug wholesalers and chain and independent drugstores, the company announced Feb. 3. "The creation of the managed health care/national accounts business unit will dramatically increase our customer orientation," Abbott VP-Pharmaceutical Operations Paul Clark commented. "Abbott will be in closer contact with these markets, allowing us to be more responsive to our customers' needs." The national accounts unit includes two specialized sales groups. A seven-person group, which has been operating for about two years to service wholesaler and chain accounts, will add responsibility for nursing home business. A second three-man group will be responsible for HMO accounts. The unit is headed by Richard Haiduck, whose 12 year career at Abbott includes general manager experience in the Far East. Most recently, he was Abbott's director of sales and marketing operations. The special sales staff has been recruited from within the company and includes personnel with experience at the district manager level. Abbott is joining a growing number of pharmaceutical firms that are setting up national accounts units to compete for the managed health system business. The national accounts structure allows drug firms to tailor products and service packages to meet the individual needs of national buying entities. "Due to the tremendous changes that have occurred in the health care system, many parties in addition to the physician make decisions regarding prescription medications," the release states. "In today's health care environment, it is not enough for a medication to be safe and efficacious. The drug must also be cost-effective." Sandoz implemented a similar program in 1986, and the firm expects to increase the number of account managers, currently at 15, to approximately 45 within the next two years. SmithKline's recent supply contract with Hospital Corporation of America was arranged by its corporate accounts office ("The Pink Sheet" Jan. 25, T&G-10). "The managed health care/national accounts group" will allow "greater focus and understanding of the critical issues facing our pharmaceutical customers," Haiduck said. "This field sales organization will be assisted by a headquarters support group that includes personnel dedicated to marketing, pharmacy information and customer service."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS013122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel